$1.68
(2.06%)
0.69%
Add to watchlist
Create an alert
Stocks and Shares ISAIonis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Company Information
About this company
Key people
Brett P. Monia
Chief Executive Officer, Director
Elizabeth L. Hougen
Chief Financial Officer, Executive Vice President - Finance
Shannon L. Devers
Chief Human Resources Officer, Executive Vice President
C. Frank Bennett
Executive Vice President, Chief Scientific Officer
Patrick R. O'Neil
Executive Vice President, Chief Legal Officer, General Counsel and Corporate Secretary
Joseph T. Baroldi
Executive Vice President, Chief Business Officer
Brian Birchler
Executive Vice President, Chief Business Officer
Richard S. Geary
Executive Vice President, Chief Development Officer
Kyle Jenne
Executive Vice President, Chief Global Product Strategy Officer
Holly Kordasiewicz
Executive Vice President and Chief Development Officer
Joseph Loscalzo
Independent Chairman of the Board
Joseph H. Wender
Lead Independent Director
B. Lynne Parshall
Director
Spencer R. Berthelsen
Independent Director
Allene M. Diaz
Independent Director
Click to see more
Key facts
- Shares in issue161.97m
- EPICIONS
- ISINUS4622221004
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$13.47bn
- Employees1,069
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.